Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 159″]

Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO & Chairman Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update on the late-stage trials of Roclatan.